About FDA
FDA-TRACK Center for Biologics Evaluation & Research
Sign up to receive FDA-TRACK email updates
The Center for Biologics Evaluation and Research (CBER) regulates biological products for human use under applicable federal laws, including the Public Health Service Act and the Federal Food, Drug and Cosmetic Act. CBER protects and advances the public health by ensuring that biological products are safe and effective and available to those who need them. CBER also provides the public with information to promote the safe and appropriate use of biological products.
FDA-TRACK CBER Program Areas and Offices
CBER has three program areas for seven offices. Click on the links below for additional information relating to these program areas and their dashboards.
FDA-TRACK CBER Cross Management Support Offices This page includes the Office of Management (OM) and the Office of Communication, Outreach and Development (OCOD). FDA-TRACK CBER Cross Program Support Offices This page includes the Office of Biostatistics and Epidemiology (OBE)and the Office of Compliance and Biologics Quality (OCBQ). FDA-TRACK CBER Research and Review Offices This page includes the Office of Blood Research and Review (OBRR), the Office of Cellular, Tissue, and Gene Therapies (OCTGT), and the Office of Vaccines Research and Review (OVRR).
Quarterly Briefing Summaries
May 2, 2012: FDA-TRACK CBER Quarterly Briefing Summary February 1, 2012: FDA-TRACK CBER Quarterly Briefing Summary November 2, 2011: FDA-TRACK CBER Quarterly Briefing Summary August 3, 2011: FDA-TRACK CBER Quarterly Briefing Summary May 9, 2011: FDA-TRACK CBER Quarterly Briefing Summary February 2, 2011: FDA-TRACK CBER Quarterly Briefing Summary
Additional Information on CBER
Contact FDA
FDA-TRACK Team
OC/OPP/Office of Planning
10903 New Hampshire Avenue
WO32 - Rm. 3357
Silver Spring, MD 20993